Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04742257 · ClinicalTrials.gov registry record · NA
Study Evaluating MyoRegulator® Treatment in Post-Stroke Upper Limb Spasticity
A NA study, sponsored by PathMaker Neurosystems.
- Terminated
- Registry status
- NA
- Development phase
- 28
- Enrollment target
NCT04742257: Clinical Trial NA study, sponsored by PathMaker Neurosystems.
NCT04742257 is a NA study that was terminated before completion, run by PathMaker Neurosystems. The registered enrollment target is 28 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04742257, a NA study, was terminated before completion, sponsored by PathMaker Neurosystems.
- TERMINATED
- Registry status
- NA
- Development phase
- 28 participants
- Enrollment target
Study Summary
This is a multi-center, randomized, double-blind (patient and evaluator), sham-controlled study to be conducted in stroke patients with upper-extremity spasticity. The main objectives of this study are to evaluate the performance and safety of the MyoRegulator® device in active- versus sham-treated patients after 5 consecutive days of treatment. The MyoRegulator® device is a non-significant risk (NSR) investigational non-invasive neuromodulation device that uses multi-site direct current (multi-site DCS) stimulation for the treatment of muscle spasticity.
Primary Outcome
The Modified Ashworth Scale is a validated clinical measurement for the evaluation of spasticity after stroke.
Interventions
- DEVICE MyoRegulator® device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2022-03-04 |
| Est. Completion | 2024-06-30 |
| Phase | NA |
Why NCT04742257 stopped before completion
NCT04742257 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which MyoRegulator® device is the first listed.
NCT04742257 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04742257 about?
NCT04742257 is a clinical study titled "Study Evaluating MyoRegulator® Treatment in Post-Stroke Upper Limb Spasticity". This is a multi-center, randomized, double-blind (patient and evaluator), sham-controlled study to be conducted in stroke patients with upper-extremity spasticity. The main objectives of this study are to evaluate the performance and safety of the MyoRegulator® device in active- versus sham-treated ...
What is the current status of trial NCT04742257?
This trial is currently terminated. It is a NA study. The enrollment target is 28 participants. The study started on 2022-03-04. Estimated completion is 2024-06-30.
What interventions are being tested in trial NCT04742257?
The interventions under investigation include: MyoRegulator® device (DEVICE).
Who is sponsoring clinical trial NCT04742257?
This trial is sponsored by PathMaker Neurosystems, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04742257's enrollment target sits among peer trials
28 1704th of 2000 higher than 293 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI